MERIT40 deficiency expands hematopoietic stem cell pools by regulating thrombopoietin receptor signaling

Hematopoietic stem cells (HSCs) comprise a rare population of cells residing in the bone marrow (BM). They have the unique capability to maintain a balance between quiescence, self-renewal, and proliferation/differentiation into multiple blood lineages. This dynamic equilibrium is essential for preserving stem cell pools throughout the life of the organism, while constantly supplying blood cells at the steady state and under stress conditions such as infection or bleeding. Cell-intrinsic regulation of signal transduction, cell cycle progression, and gene expression, as well as extrinsic factors from the microenvironment, have been implicated in regulating HSC self-renewal vs differentiation decisions. Importantly, quiescence is required to preserve HSC stemness and their long-term reconstitution ability. However, intrinsic mechanisms that regulate HSC homeostasis and cell cycle state to promote stemness remain incompletely understood.

Cytokines signaling through their cognate receptors play important roles in hematopoiesis. One such signaling axis is thrombopoietin (Tpo) and its receptor, Mpl. Tpo is the primary cytokine that regulates megakaryocyte development and platelet production.^1-3  Tpo activates Mpl in HSCs to maintain HSC quiescence and self-renewal,^4,5  and Mpl^−/− or Tpo^−/− mice exhibit reduced HSC numbers and self-renewal capability.^6-9  Furthermore, Mpl loss-of-function mutations are responsible for congenital amegakaryocytic thrombocytopenia and progressive BM failure.¹⁰  These findings established a critical role for Tpo/Mpl signaling in HSC development and functions in mice and humans.

Tpo binding to Mpl activates Janus kinase 2 (JAK2), triggering a cascade of signaling events, involving signal transducer and activator of transcription 5 (Stat5), phosphatidylinositol 3-kinase/Akt, and p44/42 mitogen-activated protein kinase.^1,11  JAK2-deficient hematopoietic cells fail to respond to Tpo and an array of hematopoietic cytokines, revealing JAK2’s essential role in cytokine receptor signaling.¹²  We and others have previously shown that the adaptor protein Lnk (also called SH2B3) negatively regulates the Tpo/Mpl/JAK2 pathway.^13-15 Lnk^−/− mice harbor a markedly expanded HSC pool, with superior reconstitution ability due to an increase in HSC self-renewal.^13,16  The effects of Lnk in HSCs are negated upon deletion of Mpl,¹³  further cementing the role of the Tpo/Mpl/JAK2 signaling axis in regulating HSC cell cycle and self-renewal.

To delineate mechanisms for Lnk function, we previously used a proteomic strategy to identify Lnk-interacting proteins.¹⁷  This approach revealed a novel interaction between Lnk and a deubiquitinating enzyme (DUB) complex, Brcc36 isopeptidase complex (BRISC).¹⁷  The BRISC DUB complex specifically hydrolyzes lysine 63–ubiquitin (K63-Ub) conjugates, a nondegradative form of Ub that has been implicated in hematopoiesis and cytokine receptor signaling.^18-20  There are 8 different possible linkages for Ub chains. K48-Ub is the canonical form that targets proteins for degradation through the proteasome.²¹  In contrast, K63-Ub does not target proteins to the proteasome, but rather, mediates various biological processes, including DNA repair,^22,23  protein trafficking,²⁴  autophagy,²⁵  and signal transduction.²⁶  An in vivo role of K63-Ub in early stages of hematopoiesis has been previously suggested based on the observation that the loss of Ubc13 (the Ub-conjugating enzyme specific for K63-Ub chains) in mice leads to hematopoietic failure owing to loss of HSCs and progenitor cells (HSPCs).²⁷  However, how K63-Ub affects hematopoiesis or HSC function has not been well established.

BRISC was first biochemically purified as a major K63-DUB activity in the cytoplasm.²⁸  The BRISC complex has recently been implicated in inflammatory cytokine signaling²⁰ ; however, a role for BRISC in hematopoiesis has not been reported. BRISC is composed of the enzyme BRCC36 and 3 core complex constituents (KIAA0157, MERIT40 [Mediator of RAP80 Interactions and Targeting 40 kDa (M40)], and BRCC45).^18,19  M40 (also called BABAM1) is the scaffold protein critical for the complex stability and DUB activity.^22,29,30  The Lnk-BRISC interaction suggests a potential role of BRISC in hematopoiesis. In this study, we investigated the potential role of M40 in regulating HSC cell cycle and self-renewal, and the underlying mechanism. Our studies revealed a novel contribution of M40 to stem cell homeostasis, thus suggesting an unappreciated role for nondegradative deubiquitination in regulating stem cell function.

C57/BL6 (CD45.2), SJL (CD45.1), and F1 (CD45.1/CD45.2) breeding pairs were from The Jackson Laboratory and maintained at the in-house facility. M40-gene trap (M40^−/−) mice on the C57/B6 background were generated by the Texas A&M Institute for Genomic Medicine. Mpl^−/− mice²  were provided by Dr Frederic de Sauvage (Genentech, South San Francisco, CA). This work was conducted under an approved protocol from the institutional animal care and use committee of Children’s Hospital of Philadelphia.

The staining procedure was performed as previously described.^13,17,31  Briefly, for the HSPC subset, BM cells were first stained with a biotinylated-lineage cocktail that contains anti-CD4, CD8, CD5, Ter119, Gr-1, Mac-1, B220, CD19, and interleukin-7 receptor (IL-7R) antibodies (eBioscience), followed by streptavidin–phycoerythrin (PE)–Texas Red secondary antibodies (Caltag Laboratories, Invitrogen) and PE-Cy5.5–conjugated anti-Sca-1, allophycocyanin (APC)–Alexa 750–Kit, APC-CD34, and PE-Flk2 (eBioscience) antibodies. For signaling lymphocyte activation molecule (SLAM) markers, PE-Cy7-CD150 and fluorescein isothiocyanate (FITC)–CD48 antibodies (Biolegend) were used. Cells were subsequently collected on a Fortessa flow cytometer (BD Biosciences), and data were analyzed using FlowJo software.

Serially diluted unfractionated total BM donor cells (CD45.2) from 2 to 3 age-matched wild-type (WT) or M40^−/− mice were mixed with 3 × 10⁵ competitor BM cells (CD45.1) and injected retro-orbitally into lethally irradiated (a split dose of 10 Gy of orthovoltage x-ray; Precision X-ray Inc) F1 recipient mice. Sixteen weeks after injection, the percentage of donor-derived cells in peripheral blood was determined by flow cytometry as previously described.¹³  Mice with donor-derived cells in the blood higher than 1% were counted as “positive reconstitution.” Data from 3 to 5 independent experiments were combined and competitive repopulation units were calculated using L-Calc software (Stemcell Technologies).

Fluorescence-activated cell sorting of HSCs for BM transplantation (BMT) was performed as described in “Flow cytometric analysis of HSPC subsets”.³²  Briefly, Lin⁻ (lineage-negative) BM cells were first enriched with Dynabeads (Invitrogen), followed by antibody staining as described above. Fifty CD34⁻CD150⁺CD48⁻ Lineage⁻Sca-1⁺Kit⁺ (LSK) HSCs were double-sorted using FACSAria (BD Biosciences) high-speed sorters, and directly deposited into 96-well plates, and subsequently transplanted with 4 × 10⁵ Sca-1–negative competitors (CD45.1) and injected into lethally irradiated F1 recipients. The percent of chimerism in peripheral blood was assessed by flow cytometry 16 weeks after BMT. Primary transplanted mice were sacrificed at 4 months, and 3000 donor LSK cells were purified and transplanted into lethally irradiated secondary recipients along with competitor cells. Cells from each primary recipient were injected into 1 to 4 secondary recipients.

WT and M40^−/− mice were injected intraperitoneally with 150 mg/kg 5-Fluorouracil (5-FU) once a week for the indicated time and moribund animals were killed according to the protocol. Identification of moribund mice for euthanasia was conducted with the assistance of the veterinarian technicians in a blinded fashion. Briefly, anorexia, lethargy, pallor, and weight loss were used as signs of stress. For the hematopoietic recovery assay, mice received a single injection of 5-FU. Complete blood counts were measured at indicated time points. HSC frequency was determined by flow cytometry 7 days after a single injection of 5-FU. Long-term HSCs (LT-HSCs) were defined as the CD34⁻Flk2⁻CD150⁺ LSK population.

To quantify colony-forming cells (CFCs), 8 × 10⁴ BM cells from WT and M40^−/− mice 1 day or 10 days after 5-FU treatments were plated in duplicate in semisolid methylcellulose (M3434; StemCell Technologies) according to the manufacturer’s protocol.

Purified CD150⁺CD48⁻LSK HSCs from WT and M40^−/− mice were sorted directly into TRIzol LS (Invitrogen). RNA was isolated using the microRNeasy kit (QIAGEN), and the microarray analysis was performed at the PENN Molecular Profiling/Genomics Facility using the GeneChip Mouse Gene 2.0ST array (Affymetrix). Resulting expression data were normalized using robust multichip analysis directly from the CEL files. Significant differential expression between the 2 groups was analyzed, and genes with significance analysis of microarray data P values < .05 were selected. Microarray data were also tested for gene set enrichment analysis (GSEA) using MSigDb c2.cp v3.0.³³ 

WT and M40^−/− mice were injected with BrdU (5′-Bromodeoxyuridine) for 2 hours or fed with BrdU (0.5 mg/mL) in drinking water for 7 days before analysis. Total BM cells were isolated and Lin⁻ckit⁺ cells were sorted using Aria. Cells were then stained with ckit-APC-Cy7, Sca1-PE, CD48-FITC, CD150-PE-Cy7, and BrdU-APC antibodies following the manufacturer’s instructions (BD Biosciences). Cells were resuspended in buffer containing DAPI (4,6 diamidino-2-phenylindole) for flow cytometry. Sorted SLAM LSK cells were incubated with 5 μg/mL Hoechst 33342 (Molecular Probes) in Hank balanced salt solution containing 20 mM HEPES (N-2-hydroxyethylpiperazine-N′-2-ethanesulfonic acid), 5 mM glucose, and 10% fetal bovine serum at 37°C for 45 minutes, followed by an additional 45 minutes of incubation with 1 μg/mL Pyronin Y (Sigma-Aldrich). Cells were subsequently analyzed on a Fortessa flow cytometer (BD Biosciences).

LSK cells from WT and M40^−/− mice were starved for 2 hours in RPMI medium (Invitrogen) supplemented with 0.5% bovine serum albumin and stimulated with 1 or 10 ng/mL mouse recombinant Tpo (PeproTech) for 10 minutes. Cell lysates were subjected to standard western blot (WB) analysis with antibodies to pStat5, pAkt, and Akt (Cell Signaling Technology), Stat5, and JAK2 (Santa Cruz Biotechnology). Cell lysates from WT and M40^−/− BM cells were subjected to WB with anti-β-actin (Santa Cruz Biotechnology), Brcc36³⁴  (Bethyl Laboratory), KIAA 0157 (Aviva), and M40²²  antibodies.

We previously found that the BRCC36-containing DUB complex BRISC associates with Lnk,¹⁷  which is an important negative regulator of Tpo/Mpl-mediated signaling in HSCs.¹³  To determine whether this interaction is involved in cytokine signaling in hematopoiesis, we generated mice deficient in M40, the scaffold protein that is critical for the integrity of this DUB complex.²² M40^−/− mice showed complete loss of M40 expression at both messenger RNA and protein levels (supplemental Figure 1, available on the Blood Web site). As predicted, protein levels of BRCC36 were markedly reduced in the BM from M40^−/− mice (supplemental Figure 1), in agreement with our published studies showing that M40 plays a scaffolding and stability function for the M40-BRCC36 containing DUB complexes.²² 

M40^−/− mice were born at the predicted Mendelian ratio with an appearance indistinguishable from their WT littermates. Complete blood counts in 8- to 12-week-old animals revealed significantly increased platelet numbers in M40-deficient mice (supplemental Figure 2). Although M40^−/− mice showed normal myeloid, T-lineage, and B-lineage distributions in the BM and spleen (supplemental Figure 2), they exhibited an elevation in the primitive hematopoietic compartment. Flow cytometric analysis demonstrated that M40^−/− mice had increased phenotypic LT-HSCs as determined by the established and most stringent HSC markers, CD150⁺CD34⁻Flk2⁻LSK (LSK) (Figure 1A), but not lineage-committed progenitors (supplemental Figure 3). Because the total BM cells remain unchanged (supplemental Figure 2), our results suggest that M40^−/− mice have increased numbers of phenotypic HSCs.

To functionally quantify HSC frequency and assess whether M40 affects HSC reconstitution potential, we used competitive limiting dilution BMT. The results revealed that M40^−/− mice indeed harbored increased numbers of functional HSCs (Figure 1B). Importantly, M40^−/− BM cells gave rise to greater donor chimerism in all blood lineages in the recipient mice (Figure 1C-D), suggesting that M40^−/− BMs have superior long-term repopulating abilities. Of note, M40 deficiency did not affect HSPC homing efficiency (supplemental Figure 4). Hence, our data strongly support that M40 deficiency leads to an expansion of phenotypic and functional HSC pool.

We transplanted purified HSCs to investigate whether the increase in repopulation observed in M40^−/− transplanted animals is due to intrinsic HSC properties rather than that of the committed progenitors. HSCs (CD34⁻CD150⁺CD48⁻LSK) from WT and M40^−/− mice were double-sorted and 50 HSCs were directly transplanted into lethally irradiated animals along with competitors. Our results demonstrate that M40^−/− HSCs exhibited superior reconstitution ability to that of WT HSCs in the primary transplants (Figure 2A).

Donor-derived HSCs are subjected to significant stress during BMT.³⁵  These normally quiescent cells must self-renew, proliferate, and differentiate to support the increased number of lineage-restricted progenitors required to reconstitute myeloid and lymphoid populations after ablation of the recipient BM. HSC concentrations and their repopulating capacity drop significantly after each round of transplant.^36-38  Thus, we performed secondary BMT to analyze stem cell self-renewal. We purified donor-derived LSKs from the primary transplants and injected them into lethally irradiated recipients. M40^−/− HSCs again displayed superior reconstitution in the secondary transplants (Figure 2B). Our data strongly suggest that M40 deficiency augments HSC intrinsic repopulating activity by increasing HSC self-renewal.

M40 deficiency increases platelet counts and HSC homeostasis at the steady state. We next subjected M40^−/− mice to cytoablative stress induced by 5-FU. M40^−/− mice were more resistant to 5-FU treatment with increased platelet recovery (supplemental Figure 5), and increased survival upon repetitive 5-FU administration (Figure 3A). One day after 5-FU treatment, M40^−/− mice showed increased clonogenic survival in comparison with WT mice (Figure 3B), suggesting that M40^−/− HSPCs are more resistant to cytoablative stress. 5-FU depletes cycling hematopoietic cells and forces primitive hematopoietic cells including HSCs to regenerate. Analysis of the stem cell compartment after 5-FU injection demonstrated that M40^−/− HSCs regenerated faster than WT HSCs upon cytotoxic stress at day 7 (Figure 3C) with increased cell proliferation as determined by BrdU incorporation assays (Figure 3D). After 2 injections of 5-FU, WT mice showed marked hypoplastic BM with progenitor cell numbers being substantially lower than those of M40^−/− mice (Figure 3E), which explains the prolonged survival due to loss of M40. Collectively, these data suggest that M40 deficiency protects HSPCs from cytotoxic stress and promotes HSC regeneration.

The proper control of HSC quiescence and cell proliferation/differentiation is critical for HSC maintenance and self-renewal ability. We thus examined HSC cell cycle kinetics using BrdU incorporation assays. In both long-term (7 days) and short-term (2 hours) BrdU labeling, M40^−/− SLAM LSKs had a marked decrease in the BrdU⁺ population compared with WT HSCs (Figure 4A). Lin⁻Kit⁺Sca-1⁻ progenitor cells as well as CD48⁺LSK multipotential progenitors were also analyzed at the same time, and the cell cycle kinetics were similar between WT and M40^−/− progenitors (data not shown). Thus, our data suggest that M40 specifically controls HSC cell cycle progression. The decreased BrdU⁺ populations observed in M40^−/− HSCs imply an increase in quiescence. To directly measure the quiescent HSC population, we stained HSCs (SLAM LSKs) with an RNA-specific dye, Pyronin Y (Py), in conjunction with a DNA-specific dye, Hoechst 33342 (Ho), to differentiate G0 from G1 populations. The G0 fraction is defined by Py^lowHo^low cells representing low RNA amounts and 2N DNA content.³⁹  Consistent with our BrdU experiment, M40^−/− HSCs exhibited a larger G0 population than WT HSCs (Figure 4B). Together, our data suggest that loss of M40 slows the cell cycle and acquires HSC quiescence.

To investigate the molecular mechanisms by which M40 regulates the HSC cell cycle, we performed genome-wide transcriptome analysis using sorted SLAM LSKs from WT and M40^−/− mice. GSEA³³  revealed, and reverse transcription–quantitative polymerase chain reaction (RT-qPCR) confirmed, that M40^−/− HSCs showed downregulation in gene sets associated with cell cycle, mitosis, DNA replication pathways (Figure 4C-D, supplemental Table 1). Furthermore, the top 5 most significantly downregulated Gene Ontology (GO) terms in the biological process in M40^−/− HSCs were associated with cell division (supplemental Table 2). Thus, the gene expression signature is consistent with a role for M40 in controlling the HSC cell cycle.

Lnk deficiency stimulates the major Mpl-controlled signaling pathways involving Stats and Akt in megakaryocytes⁴⁰  and HSCs.¹³  Given the physical association of Lnk and M40, we examined whether the HSPC response to Tpo is affected by the loss of M40. Purified LSKs from WT and M40^−/− animals were stimulated with varying concentrations of Tpo for 10 minutes following serum starvation. Western blot analysis with antibodies specific for activated phospho-JAK2, Stat5, and Akt demonstrated that M40^−/− HSPCs were more sensitive to Tpo than WT HSPCs in activating Tpo downstream signaling pathways (Figure 5). These results indicate that M40 negatively regulates Tpo-mediated signaling in HSCs consistent with a Lnk-associated function.

Mice deficient for M40 harbor elevated numbers of LT-HSCs and circulating platelets, both of which depend on Mpl signaling triggered by Tpo. Therefore, our finding of increased sensitivity to Tpo in M40^−/− LSK cells is consistent with a role for M40 in regulating Tpo/Mpl signaling. To genetically test this hypothesis, we generated mice deficient in both Mpl and M40 (Mpl^−/−M40^−/−). We found that Mpl and M40 double nullizygous mice resembled Mpl single null mice showing a marked decrease in platelet counts and HSC numbers (Figure 6), attesting that M40 functions through Tpo/Mpl signaling in HSCs.

In this study, we investigated the role of the adaptor protein M40 in hematopoiesis and cytokine signaling in HSPCs. M40 deficiency increases the numbers of phenotypic and functional LT-HSCs. Purified M40^−/− HSCs exhibit a superior reconstituting potential to WT HSCs, indicating that M40 plays a cell-intrinsic role in HSC expansion. Loss of M40 provides a survival advantage in response to cytotoxic challenge, demonstrating M40 is critical for HSC regeneration under both steady-state and stress conditions. Similar to Lnk deficiency,⁴¹ M40^−/− mice harbor an expanded HSC pool with increased quiescence, superior multilineage reconstitution, and serial transplantability. This phenotype is rare among mouse models with elevated HSC activity. Therefore, understanding M40 regulatory functions in HSCs will provide significant insights into stem cell biology.

It is of interest that M40^−/− mice harbor a more quiescent and yet expanded pool of HSCs. One plausible explanation is that quiescent M40^−/− HSCs undergo increased self-renewal divisions than WT HSCs. The BrdU incorporation assay does not differentiate self-renewal from non-self-renewal divisions. Quantification of the functional stem cell pool by both phenotypic and transplant assays suggests that M40^−/− HSCs have increased self-renewal divisions to achieve increased HSC numbers under homeostatic conditions. Because M40 deficiency leads to a larger stem cell pool, a smaller proportion of HSCs contributes to non-self-renewing divisions or proliferation/differentiation to maintain hematopoiesis. This interpretation is compatible with the decelerated cell cycle observed in M40^−/− HSCs. Genome-wide gene expression profiling in M40^−/− HSCs showed downregulation of genes important for cell cycle progression, DNA replication, and mitosis, which is consistent with its role in controlling HSC cell cycle. M40^−/− HSCs are hypersensitive to Tpo in activating downstream signaling. Importantly, the effect of M40 on HSCs was abrogated on an Mpl null background, indicating a role for M40 in Tpo/Mpl-mediated HSC homeostasis. It has been shown that Tpo provides an osteoblastic niche signal that keeps HSCs in quiescence.^4,5  The Tpo/Mpl axis is reminiscent of Ang-1/Tie2 function in HSCs, in that Ang-1 enhances HSC quiescence and fosters the interaction with the BM niche to protect the HSC compartment from myelosuppressive stress.⁴²  However, the pathways by which these 2 signaling systems impact on HSCs are likely distinct.

HSCs are largely dormant under steady-state conditions. Quiescent or slow-cycling HSCs are poised and ready to proliferate upon stress. Dormant HSCs display superior reconstitution potential in transplant experiments.^43-49  HSC engraftment capacity is a function of the cell cycle such that quiescent HSCs engraft better than their counterparts in S/M/G2.⁵⁰  Moreover, HSC divisional history correlates with HSC activity, and temporal quiescence is a better predictor of function than cell-surface phenotype.⁵¹  Hence we infer that the increased numbers of quiescent HSCs found in M40^−/− mice account for their enhanced response to challenges such as 5-FU treatment or transplantation into lethally irradiated hosts. The protection of mice from 5-FU–induced lethality afforded by M40 deficiency may not be solely attributed to HSC quiescence. In fact, we showed that M40^−/− HSPCs exhibited better colonogenic survival. Furthermore, M40^−/− HSCs are quiescent but yet poised to undergo rapid proliferation upon 5-FU stress. Additional insights on the relationship between HSC cell cycle status and self-renewal can be gleaned from other mouse models. Mice deficient for Mpl,^4,5  Foxo3a,⁵²  PTEN,⁵³  HIF,⁵⁴  Fbw7,⁵⁵  Necdin,⁵⁶  or p57⁵⁷  all exhibit defective maintenance of quiescence and increased cycling, leading to impaired self-renewal and a loss of competitive repopulating capacity. To our knowledge, Lnk^−/− and M40^−/− mice are the only mouse models showing increased quiescence but enhanced self-renewal and superior reconstitution ability. We found that both Lnk and M40 act through the Tpo/Mpl pathway, attesting to the importance of Tpo/mpl in protecting HSC quiescence and promoting self-renewal.

Cytokine signaling is regulated by posttranslational modifications, such as phosphorylation and ubiquitination, to enable rapid transduction of extracellular cues. A role for protein ubiquitination in stem cell homeostasis has begun to emerge.⁵⁸  Characterization of mouse models with deletion of Ub ligases showed hematopoietic perturbations often caused by failure to target selected proteins for proteosomal degradation^54,59-61  and causing dysregulation of the stem cell compartment. For example, lack of Cbl led to elevated HSPC numbers with increased repopulating activities and augmented proliferation in response to Tpo.⁶²  Similarly, increased numbers of HSPCs with high proliferative potential were reported in mice deficient in Itch, an E3 ligase for Notch.⁶³  Furthermore, mice deficient in Fbw7, an E3 ligase for Myc, have functionally impaired HSPC, an increased fraction of cycling HSCs, and decreased expression of genes associated with HSC self-renewal phenotype.^55,64  Ubiquitination is a reversible process, as DUBs can rapidly deconjugate ubiquitinated substrates.⁶⁵  Deletion of Mysm, a DUB for histone H2A, results in loss of HSC quiescence and stem cell exhaustion.⁶⁶  These examples illustrate the complex effects of protein ubiquitination on stem cell maintenance and functions.

M40 is essential for the integrity of complexes with K63-DUB activity, suggesting a previously unrecognized role for nondegradative ubiquitination in regulating stem cell activity. Consistent with a role for K63-ubiquitination in protein activity rather than proteosomal degradation, we detected increased phosphorylation of JAK2, STAT5, and Akt but not total protein levels. Increased Tpo-mediated signaling in M40^−/− HSPCs suggests that component(s) of Tpo/Mpl/JAK2 signaling pathway are likely subjected to regulation by M40-associated DUB activities. Our genetic experiments showed that M40 negatively regulates Mpl signaling, and that M40’s effects on HSCs are dependent upon the Mpl pathway. Moreover, our previous biochemical studies showed physical interaction between Lnk, JAK2, and the M40 complex.^13,17  Together, these results are consistent with a role of M40 in the Tpo/Mpl/JAK2/Lnk signaling pathway. We recently reported that one of the M40-associated complexes, BRISC, localizes to and deubiquitinates actively engaged interferon receptor, thus limiting its K63-Ub–mediated internalization.²⁰  However, we failed to detect any changes in cell surface expression or endocytosis of the Mpl receptor in M40 null HSPCs (data not shown). Future investigation is warranted to pinpoint the exact targets of the M40 complex in HSCs.

Allogeneic HSPC transplantation is standard of care for a variety of hematopoietic malignancies and congenital blood diseases.⁶⁷  However, a majority of patients remain ineligible for conventional allogeneic HSPC transplantation due to the lack of appropriately matched donors. The use of umbilical cord blood as a source of allogeneic HSPC has expanded the donor pool. However, it is associated with delayed engraftment and failure to engraft. Despite extensive research efforts, the process of stem cell expansion is not fully understood. Cytokine therapy may not only enhance the production of mature hematopoietic cells, but also improve the engraftment and expansion of HSCs. DUBs are specialized proteases that have emerged as potential “druggable” targets. Thus, our studies might yield novel pharmacologic strategies that could be used for controlled stem cell expansion for transplantation without malignant transformation. In conclusion, this study has identified M40 as a novel HSC regulator, suggesting an unappreciated role for nondegradative deubiquitination in regulating stem cell function.

The authors thank the Human Hematopoietic Stem Cell Center of Excellence P30DK090969 for its support of microarray analysis, and are grateful to Dr Gerd Blobel for critical review of the manuscript.

W.T. was supported by National Institutes of Health, National Heart, Lung, and Blood Institute grants R01HL095675 and R01HL110806, as well as awards from the Myeloproliferative Neoplasm Research Foundation and Gabrielle’s Angel Foundation for Cancer Research. R.A.G. is supported by National Institutes of Health, National Cancer Institute grant R01CA138835. K.R. is supported by National Institutes of Health, National Heart, Lung, and Blood Institute grant T32HL007150.

W.T. is a Leukemia & Lymphoma Society Scholar. K.R. and J.J. were American Heart Association postdoctoral fellows.

Contribution: K.R. and W.T. designed and performed the experiments, analyzed the data, and wrote the manuscript; J.J. and R.D. performed experiments; and B.A. and R.A.G. generated M40^−/− mice and edited the manuscript.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Wei Tong, Children’s Hospital of Philadelphia, Abramson Building, Suite 316A, 3615 Civic Center Blvd, Philadelphia, PA 19104-4318; e-mail: tongw@email.chop.edu.